<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36982902</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5828</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24065828</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is regarded as a fatal neurodegenerative disease that is featured by progressive damage of the upper and lower motor neurons. To date, over 45 genes have been found to be connected with ALS pathology. The aim of this work was to computationally identify unique sets of protein hydrolysate peptides that could serve as therapeutic agents against ALS. Computational methods which include target prediction, protein-protein interaction, and peptide-protein molecular docking were used. The results showed that the network of critical ALS-associated genes consists of ATG16L2, SCFD1, VAC15, VEGFA, KEAP1, KIF5A, FIG4, TUBA4A, SIGMAR1, SETX, ANXA11, HNRNPL, NEK1, C9orf72, VCP, RPSA, ATP5B, and SOD1 together with predicted kinases such as AKT1, CDK4, DNAPK, MAPK14, and ERK2 in addition to transcription factors such as MYC, RELA, ZMIZ1, EGR1, TRIM28, and FOXA2. The identified molecular targets of the peptides that support multi-metabolic components in ALS pathogenesis include cyclooxygenase-2, angiotensin I-converting enzyme, dipeptidyl peptidase IV, X-linked inhibitor of apoptosis protein 3, and endothelin receptor ET-A. Overall, the results showed that AGL, APL, AVK, IIW, PVI, and VAY peptides are promising candidates for further study. Future work would be needed to validate the therapeutic properties of these hydrolysate peptides by in vitro and in vivo approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fatoki</LastName><ForeName>Toluwase Hezekiah</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0003-3202-9855</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Federal University Oye-Ekiti, PMB 373, Oye 371104, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chukwuejim</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Federal University Oye-Ekiti, PMB 373, Oye 371104, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udenigwe</LastName><ForeName>Chibuike C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-8802-7707</Identifier><AffiliationInfo><Affiliation>Faculty of Health Sciences, School of Nutrition Sciences, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biomolecular Sciences, Faculty of Science, University of Ottawa, Ottawa, ON K1N 6N5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aluko</LastName><ForeName>Rotimi E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-9025-2513</Identifier><AffiliationInfo><Affiliation>Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Richardson Centre for Food Technology and Research, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CRC-2020-00290</GrantID><Agency>Canada Research Chairs</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500506">KIF5A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C522215">FIG4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005420">Flavoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005420" MajorTopicYN="N">Flavoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">associated genes</Keyword><Keyword MajorTopicYN="N">hydrolysate peptides</Keyword><Keyword MajorTopicYN="N">metabolic</Keyword><Keyword MajorTopicYN="N">molecular docking</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">supplements</Keyword><Keyword MajorTopicYN="N">target prediction</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36982902</ArticleId><ArticleId IdType="pmc">PMC10058213</ArticleId><ArticleId IdType="doi">10.3390/ijms24065828</ArticleId><ArticleId IdType="pii">ijms24065828</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saez-Atienzar S., Bandres-Ciga S., Langston R.G., Kim J.J., Choi S.W., Reynolds R.H., International ALS Genomics Consortium. ITALSGEN. Abramzon Y., Dewan R., et al. Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Sci. Adv. 2021;7:eabd9036. doi: 10.1126/sciadv.abd9036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd9036</ArticleId><ArticleId IdType="pmc">PMC7810371</ArticleId><ArticleId IdType="pubmed">33523907</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y.C., Feuer R., Cashman N., Luo H. Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis? Front. Mol. Neurosci. 2018;11:63. doi: 10.3389/fnmol.2018.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00063</ArticleId><ArticleId IdType="pmc">PMC5857577</ArticleId><ArticleId IdType="pubmed">29593492</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Quansah E., Karikari T.K. Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies. BioMed Res. Int. 2015;2015:298409. doi: 10.1155/2015/298409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/298409</ArticleId><ArticleId IdType="pmc">PMC4549542</ArticleId><ArticleId IdType="pubmed">26347879</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna J., Diagana M., Aissa L.A., Tazir M., Pacha L.A., Kacem I., Gouider R., Henning F., Basse A., Cisse O., et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: The TROPALS study. J. Neurol. Neurosurg. Psychiatry. 2018;90:20&#x2013;29. doi: 10.1136/jnnp-2018-318469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318469</ArticleId><ArticleId IdType="pubmed">30242088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatoki T.H., Chukwuejim S., Ibraheem O., Oke C., Ejimadu B., Olaoye I., Oyegbenro O., Salami T., Basorun R., Oluwadare O., et al. Harmine and 7,8-dihydroxyflavone synergistically suitable for amyotrophic lateral sclerosis management: An insilico study. Res. Results Pharmacol. 2022;8:49&#x2013;61. doi: 10.3897/rrpharmacology.8.83332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3897/rrpharmacology.8.83332</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R., Wiedau M. Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2020;13:98. doi: 10.3389/fnmol.2020.00098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00098</ArticleId><ArticleId IdType="pmc">PMC7296057</ArticleId><ArticleId IdType="pubmed">32581709</ArticleId></ArticleIdList></Reference><Reference><Citation>Smukowski S.N., Maioli H., Latimer C.S., Bird T.D., Jayadev S., Valdmanis P.N. Progress in Amyotrophic Lateral Sclerosis Gene Discovery. Neurol. Genet. 2022;8:e669. doi: 10.1212/NXG.0000000000000669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000669</ArticleId><ArticleId IdType="pmc">PMC9128037</ArticleId><ArticleId IdType="pubmed">35620141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun F.W., Liu B.H.M., Long X., Leung H.W., Leung G.H.D., Mewborne Q.T., Gao J., Shneyderman A., Ozerov I.V., Wang J., et al. Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics&#x2013;An AI-Enabled Biological Target Discovery Platform. Front. Aging Neurosci. 2022;14:914017. doi: 10.3389/fnagi.2022.914017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.914017</ArticleId><ArticleId IdType="pmc">PMC9273868</ArticleId><ArticleId IdType="pubmed">35837482</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A., Ruiz M.D.V.P., Perez D.I., Gil C. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs. 2017;26:403&#x2013;414. doi: 10.1080/13543784.2017.1302426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1302426</ArticleId><ArticleId IdType="pubmed">28277881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro E.P., Brooks B.R., Cummings J., Schiffer R., Thisted R.A., Wynn D., Hepner A., Kaye R. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann. Neurol. 2010;68:693&#x2013;702. doi: 10.1002/ana.22093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22093</ArticleId><ArticleId IdType="pubmed">20839238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape J.A., Grose J.H. The effects of diet and sex in amyotrophic lateral sclerosis. Rev. Neurol. 2020;176:301&#x2013;315. doi: 10.1016/j.neurol.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.09.008</ArticleId><ArticleId IdType="pmc">PMC8915943</ArticleId><ArticleId IdType="pubmed">32147204</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., et al. Trial of Sodium Phenylbutyrate&#x2013;Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E., Grosso G., Nieves J.W., Zangh&#xec; A., Factor-Litvak P., Mitsumoto H. Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients. 2021;13:2273. doi: 10.3390/nu13072273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072273</ArticleId><ArticleId IdType="pmc">PMC8308334</ArticleId><ArticleId IdType="pubmed">34209133</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscaritoli M., Kushta I., Molfino A., Inghilleri M., Sabatelli M., Fanelli F.R. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition. 2012;28:959&#x2013;966. doi: 10.1016/j.nut.2012.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2012.01.011</ArticleId><ArticleId IdType="pubmed">22677356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Rene F., Gonzalez de Aguilar J.L., Loeffler J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobak S. Nutritional Care of the Patient with Amyotrophic Lateral Sclerosis. Pract. Gastroenterol. 2022;XLVI:60&#x2013;67.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-S&#xe1;nchez S., Valiente N., Sese&#xf1;a S., Cabrera-Pinto M., Rodriguez A., Aranda A., Palop L., Fernandez-Martos C.M. Ozone modified hypothalamic signaling enhancing thermogenesis in the TDP-43A315T transgenic model of Amyotrophic Lateral. Sci. Rep. 2022;12:20814. doi: 10.1038/s41598-022-25033-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-25033-4</ArticleId><ArticleId IdType="pmc">PMC9718766</ArticleId><ArticleId IdType="pubmed">36460700</ArticleId></ArticleIdList></Reference><Reference><Citation>Millward D.J., Layman D.K., Tome D., Schaafsma G. Protein quality assessment: Impact of expanding understanding of protein and amino acid needs for optimal health. Am. J. Clin. Nutr. 2008;87:1576S&#x2013;1581S. doi: 10.1093/ajcn/87.5.1576S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/87.5.1576S</ArticleId><ArticleId IdType="pubmed">18469291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatoki T.H., Aluko R.E., Udenigwe C.C. In silico investigation of molecular targets, pharmacokinetics, and biological activities of chicken egg ovalbumin protein hydrolysates. J. Food Bioact. 2022;17:34&#x2013;48. doi: 10.31665/JFB.2022.17302.</Citation><ArticleIdList><ArticleId IdType="doi">10.31665/JFB.2022.17302</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver N., Hamill M., Samayoa P., Hou J., Hamm L., Berry D. Nutritive Polypeptides, Formulations and Methods for Treating Disease and Improving Muscle Health and Maintenance. (WO2014134225A2, PCT/US2014/018807) International Patient. 2014 September 4;:1&#x2013;271.</Citation></Reference><Reference><Citation>Combaret L., Dardevet D., Bechet D., Taillandier D., Mosoni L., Attaix D. Skeletal muscle proteolysis in aging. Curr. Opin. Clin. Nutr. Metab. Care. 2009;12:37&#x2013;41. doi: 10.1097/MCO.0b013e32831b9c31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0b013e32831b9c31</ArticleId><ArticleId IdType="pubmed">19057185</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchward-Venne T.A., Burd N.A., Mitchell C.J., West D.W., Philp A., Marcotte G.R., Baker S.K., Baar K., Phillips S.M. Supplementation of a suboptimal protein dose with leucine or essential amino acids: Effects on myofibrillar protein synthesis at rest and following resistance exercise in men. J. Physiol. 2012;590:2751&#x2013;2765. doi: 10.1113/jphysiol.2012.228833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.228833</ArticleId><ArticleId IdType="pmc">PMC3424729</ArticleId><ArticleId IdType="pubmed">22451437</ArticleId></ArticleIdList></Reference><Reference><Citation>Magne H., Savary-Auzeloux I., Migne C., Peyron M.A., Combaret L., Remond D., Dardevet D. Unilateral hindlimb casting induced a delayed generalized muscle atrophy during rehabilitation that is prevented by a whey or a high protein diet but not a free leucine-enriched diet. PLoS ONE. 2013;8:e70130. doi: 10.1371/journal.pone.0070130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0070130</ArticleId><ArticleId IdType="pmc">PMC3754992</ArticleId><ArticleId IdType="pubmed">24015173</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis D.A., Cox P.A., Banack S.A., Lecusay P.D., Garamszegi S.P., Hagan M.J., Powell J.T., Metcalf J.S., Palmour R.M., Beierschmitt A., et al. L-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND. J. Neuropathol. Exp. Neurol. 2020;79:393&#x2013;406. doi: 10.1093/jnen/nlaa002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa002</ArticleId><ArticleId IdType="pmc">PMC7092359</ArticleId><ArticleId IdType="pubmed">32077471</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Kiaei M., Damiano M., Hiller A., Wille E., Manfredi G., Calingasan N.Y., Szeto H.H., Beal M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2006;98:1141&#x2013;1148. doi: 10.1111/j.1471-4159.2006.04018.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04018.x</ArticleId><ArticleId IdType="pubmed">16895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Post J., Kogel V., Schaffrath A., Lohmann P., Shah N.J., Langen K.-J., Willbold D., Willuweit A., Kutzsche J. A Novel Anti-Inflammatory D-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. Molecules. 2021;26:1590. doi: 10.3390/molecules26061590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26061590</ArticleId><ArticleId IdType="pmc">PMC7999518</ArticleId><ArticleId IdType="pubmed">33805709</ArticleId></ArticleIdList></Reference><Reference><Citation>Layman D.K., Anthony T.G., Rasmussen B.B., Adams S.H., Lynch C.J., Brinkworth G.D., Davis T.A. Defining meal requirements for protein to optimize metabolic roles of amino acids. Am. J. Clin. Nutri. 2015;101:1330S&#x2013;1338S. doi: 10.3945/ajcn.114.084053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.114.084053</ArticleId><ArticleId IdType="pmc">PMC5278948</ArticleId><ArticleId IdType="pubmed">25926513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M.C., Kwak S.G., Park J.S., Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: A PRISMA-compliant meta-analysis. Medicine. 2021;100:e26751. doi: 10.1097/MD.0000000000026751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000026751</ArticleId><ArticleId IdType="pmc">PMC8322535</ArticleId><ArticleId IdType="pubmed">34397718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R., Crippa V., Cicardi M.E., Tedesco B., Ferrari V., Chierichetti M., Casarotto E., Piccolella M., Messi E., Galbiati M., et al. A Crucial Role for the Protein Quality Control System in Motor Neuron Diseases. Front. Aging Neurosci. 2020;12:191. doi: 10.3389/fnagi.2020.00191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00191</ArticleId><ArticleId IdType="pmc">PMC7385251</ArticleId><ArticleId IdType="pubmed">32792938</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen P.H., Ramamoorthy A., Sahoo B.R., Zheng J., Faller P., Straub J.E., Dominguez L., Shea J.-E., Dokholyan N.V. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer&#x2019;s Disease, Parkinson&#x2019;s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chem. Rev. 2021;121:2545&#x2013;2647. doi: 10.1021/acs.chemrev.0c01122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.0c01122</ArticleId><ArticleId IdType="pmc">PMC8836097</ArticleId><ArticleId IdType="pubmed">33543942</ArticleId></ArticleIdList></Reference><Reference><Citation>Megat S., Mora N., Sanogo J., Catanese A., Alami N.O., Freischmidt A., Mingaj X., de Calbiac H., Muratet F., Dirrig-Grosch S., et al. Loss of nucleoporin Nup50 is a risk factor for amyotrophic lateral sclerosis. medRxiv. 2021 doi: 10.1101/2021.08.23.21262299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.23.21262299</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khleifat A., Iacoangeli A., van Vugt J., Bowles H., Moisse M., Zwamborn R.A.J., van der Spek R.A.A., Shatunov A., Cooper-Knock J., Topp S., et al. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom. Med. 2022;7:8. doi: 10.1038/s41525-021-00267-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-021-00267-9</ArticleId><ArticleId IdType="pmc">PMC8799638</ArticleId><ArticleId IdType="pubmed">35091648</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W.L., Dittlau K.S., Bosch L.V.D. Axonal Transport Defects and Neurodegeneration: Molecular Mechanisms and Therapeutic Implications. Semin. Cell Dev. Biol. 2019;99:133&#x2013;150. doi: 10.1016/j.semcdb.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.07.010</ArticleId><ArticleId IdType="pubmed">31542222</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G.A., Bosco D.A., Brown H., Gatto R.G., Kaminska A., Song Y., Molla L., Baker L., Marangoni M.N., Berth S., et al. Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase. PLoS ONE. 2013;8:e65235. doi: 10.1371/journal.pone.0065235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065235</ArticleId><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs K.L., Kalmar B., Rhymes E.R., Fellows A.D., Ahmed M., Whiting P., Davies C.H., Greensmith L., Schiavo G. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q., Holler C.J., Taylor G., Hudson K.F., Watkins W., Gearing M., Ito D., Murray M.E., Dickson D.W., Seyfried N.T., et al. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J. Neurosci. 2014;34:7802&#x2013;7813. doi: 10.1523/JNEUROSCI.0172-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0172-14.2014</ArticleId><ArticleId IdType="pmc">PMC4044245</ArticleId><ArticleId IdType="pubmed">24899704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Str&#xf6;m A.L., Fukada K., Lee S., Hayward L.J., Zhu H. Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex. J. Biol. Chem. 2007;282:16691&#x2013;16699. doi: 10.1074/jbc.M609743200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M609743200</ArticleId><ArticleId IdType="pubmed">17403682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Chen S., Song L., Tang Y., Shen Y., Jia L., Le W. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10:588&#x2013;602. doi: 10.4161/auto.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.27710</ArticleId><ArticleId IdType="pmc">PMC4091147</ArticleId><ArticleId IdType="pubmed">24441414</ArticleId></ArticleIdList></Reference><Reference><Citation>Latysheva N.S., Babu M.M. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. 2016;44:4487&#x2013;4503. doi: 10.1093/nar/gkw282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw282</ArticleId><ArticleId IdType="pmc">PMC4889949</ArticleId><ArticleId IdType="pubmed">27105842</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghav Y., Dilliot A.A., Petrozziello T., Kim S.E., Berry J.D., Cudkowicz M.E., Vakili K., NYGC ALS Consortium. Fraenkel E., Farhan S.M., et al. Identification of gene fusions associated with amyotrophic lateral sclerosis. medRxiv. 2022 doi: 10.1101/2022.06.04.22275962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.04.22275962</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C., Sedlmeier R., Meyer T., Homberg V., Sperfeld A.D., Kurt A., Prudlo J., Peraus G., Hanemann C.O., Stumm G., et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63:724&#x2013;726. doi: 10.1212/01.WNL.0000134608.83927.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000134608.83927.B1</ArticleId><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Yilmaz R., M&#xfc;ller K., Grehl T., Petri S., Meyer T., Grosskreutz J., Weydt P., Ruf W., Neuwirth C., et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141:688&#x2013;697. doi: 10.1093/brain/awx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba K., Ori-McKenney K.M., Niwa S., McKenney R.J. Reconstitution of a Synergistic Kinesin-1 Activation Mechanism. Cell Rep. 2022;39:110900. doi: 10.1016/j.celrep.2022.110900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110900</ArticleId><ArticleId IdType="pmc">PMC9365671</ArticleId><ArticleId IdType="pubmed">35649356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant C.D., Parameswarn J., Rao L., Loss I., Chilukuri G., Parlato R., Shi L., Glass J.D., Bassell G.J., Koch P., et al. ALS-linked KIF5A &#x394;Exon27 mutant causes neuronal toxicity through gain-of-function. EMBO Rep. 2022;23:e54234. doi: 10.15252/embr.202154234.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202154234</ArticleId><ArticleId IdType="pmc">PMC9346498</ArticleId><ArticleId IdType="pubmed">35735139</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano J., Chiba K., Niwa S. An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity. Genes Cells. 2022;27:421&#x2013;435. doi: 10.1111/gtc.12936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12936</ArticleId><ArticleId IdType="pmc">PMC9322661</ArticleId><ArticleId IdType="pubmed">35430760</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E., Rajasekaran R. Rational design of linear tripeptides against the aggregation of human mutant SOD1 protein causing amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;405:116425. doi: 10.1016/j.jns.2019.116425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.116425</ArticleId><ArticleId IdType="pubmed">31422280</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G., Campagne C., Delevoye C. Skin Whitening Peptide Agents. (WO2016034541A1) International Patent . 2016 March 10;:1&#x2013;37.</Citation></Reference><Reference><Citation>Pampanin D.M., Larssen E., Provan F., Sivertsvik M., Ruoff P., Sydnes M.O. Detection of small bioactive peptides from Atlantic herring (Clupea harengus L.) Peptides. 2012;34:423&#x2013;426. doi: 10.1016/j.peptides.2012.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2012.02.005</ArticleId><ArticleId IdType="pubmed">22342594</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampanin D.M., Haarr M.B., Sydnes M.O. Natural peptides with antioxidant activity from Atlantic cod and Atlantic salmon residual material. Int. J. Appl. Res. Nat. Prod. 2016;9:1&#x2013;8.</Citation></Reference><Reference><Citation>Petersen M.C., Nielsen M.S., Jacobsen C., Tauris J., Jacobsen L., Gliemann J., Moestrup S.K., Madsen P.S. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J. 1999;18:595&#x2013;604. doi: 10.1093/emboj/18.3.595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.3.595</ArticleId><ArticleId IdType="pmc">PMC1171152</ArticleId><ArticleId IdType="pubmed">9927419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazella J., Petrault O., Lucas G., Deval E., Beraud-Dufour S., Gandin C., El-Yacoubi M., Widmann C., Guyon A., Chevet E., et al. Spadin, a Sortilin Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug Design. PLoS Biol. 2010;8:e1000355. doi: 10.1371/journal.pbio.1000355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000355</ArticleId><ArticleId IdType="pmc">PMC2854129</ArticleId><ArticleId IdType="pubmed">20405001</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurteaux C., Mazella J., Borsotto M. Spadin, a Sortilin-derived peptide: A new concept in the antidepressant drug design. OCL. 2011;18:202&#x2013;207. doi: 10.1051/ocl.2011.0395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/ocl.2011.0395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995;15:7539&#x2013;7547. doi: 10.1523/JNEUROSCI.15-11-07539.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.15-11-07539.1995</ArticleId><ArticleId IdType="pmc">PMC6578063</ArticleId><ArticleId IdType="pubmed">7472505</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., Storm D., Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 2000;20:4030&#x2013;4036. doi: 10.1523/JNEUROSCI.20-11-04030.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-11-04030.2000</ArticleId><ArticleId IdType="pmc">PMC6772651</ArticleId><ArticleId IdType="pubmed">10818138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesler J., Sari Y. Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer&#x2019;s disease. Open J. Neurosci. 2013;3:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686488</ArticleId><ArticleId IdType="pubmed">23795307</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Bollati C., Bartolomei M., Mazzolari A., Arnoldi A., Vistoli G., Lammi C. Hempseed (Cannabis sativa) Peptide H3 (IGFLIIWV) Exerts Cholesterol-Lowering Effects in Human Hepatic Cell Line. Nutrients. 2022;14:1804. doi: 10.3390/nu14091804.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14091804</ArticleId><ArticleId IdType="pmc">PMC9101684</ArticleId><ArticleId IdType="pubmed">35565772</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Chamorro I., Santos-S&#xe1;nchez G., Bollati C., Bartolomei M., Li J., Arnoldi A., Lammi C. Hempseed (Cannabis sativa) Peptides WVSPLAGRT and IGFLIIWV Exert Anti-inflammatory Activity in the LPS-Stimulated Human Hepatic Cell Line. J. Agric. Food Chem. 2022;70:577&#x2013;583. doi: 10.1021/acs.jafc.1c07520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.1c07520</ArticleId><ArticleId IdType="pmc">PMC8778635</ArticleId><ArticleId IdType="pubmed">35007086</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayaraghavan J., Scicli A.G., Carretero O.A., Slaughter C., Moomaw C., Hersh L.B. The Hydrolysis of Endothelins by Neutral Endopeptidase 24.11 (Enkephalinase) J. Biol. Chem. 1990;265:14150&#x2013;14155. doi: 10.1016/S0021-9258(18)77280-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)77280-3</ArticleId><ArticleId IdType="pubmed">2201681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones C.R., Hiley C.R., Pelton J.T., Miller R.C. Endothelin receptor heterogeneity; structure activity, autoradiographic and functional studies. J. Recept. Res. 1991;11:299&#x2013;310. doi: 10.3109/10799899109066409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10799899109066409</ArticleId><ArticleId IdType="pubmed">1653336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranno E., D&#x2019;Antoni S., Spatuzza M., Berretta A., Laureanti F., Bonaccorso C.M., Pellitteri R., Longone P., Spalloni A., Iyer A.M., et al. Endothelin-1 is over-expressed in amyotrophic lateral sclerosis and induces motor neuron cell death. Neurobiol. Dis. 2014;65:160&#x2013;171. doi: 10.1016/j.nbd.2014.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.01.002</ArticleId><ArticleId IdType="pubmed">24423643</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antoni S., Ranno E., Spatuzza M., Cavallaro S., Catania M.V. Endothelin-1 induces degeneration of cultured motor neurons through a mechanism mediated by nitric oxide and PI3K/Akt pathway. Neurotox/Res. 2017;32:58&#x2013;70. doi: 10.1007/s12640-017-9711-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-017-9711-3</ArticleId><ArticleId IdType="pubmed">28285347</ArticleId></ArticleIdList></Reference><Reference><Citation>Okeke E.B., Abioye R.O., Ventura-Santana E., Sun X., Udenigwe C.C. TNKPVI, a Putative Bioaccessible Pharmacophore of Anti-Inflammatory Potato Patatin-Derived Decapeptide DIKTNKPVIF. Molecules. 2022;27:3869. doi: 10.3390/molecules27123869.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27123869</ArticleId><ArticleId IdType="pmc">PMC9229791</ArticleId><ArticleId IdType="pubmed">35744990</ArticleId></ArticleIdList></Reference><Reference><Citation>Pa&#x142;asz A., Rojczyk E., Bogus K., Worthington J.J., Wiaderkiewicz R. The novel neuropeptide phoenixin is highly co-expressed with nesfatin-1 in the rat hypothalamus, an immunohistochemical study. Neurosci. Lett. 2015;592:17&#x2013;21. doi: 10.1016/j.neulet.2015.02.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2015.02.060</ArticleId><ArticleId IdType="pubmed">25736948</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich T., Schalla M.A., Scharner S., K&#xfc;hne S.G., Goebel-Stengel M., Kobelt P., Rose M., Stengel A. Intracerebroventricular injection of phoenixin alters feeding behavior and activates nesfatin-1 immunoreactive neurons in rats. Brain Res. 2019;1715:188&#x2013;195. doi: 10.1016/j.brainres.2019.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.03.034</ArticleId><ArticleId IdType="pubmed">30930149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei P., Keller C., Li L. Neuropeptides in gut-brain axis and their influence on host immunity and stress. Comput. Struct. Biotechnol. J. 2020;18:843&#x2013;885. doi: 10.1016/j.csbj.2020.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.02.018</ArticleId><ArticleId IdType="pmc">PMC7160382</ArticleId><ArticleId IdType="pubmed">32322366</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman D.B., Rothstein J.D. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. 2000;48:792&#x2013;795. doi: 10.1002/1531-8249(200011)48:5&lt;792::AID-ANA14&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200011)48:5&lt;792::AID-ANA14&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">11079544</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 Inhibition Protects Motor Neurons and Prolongs Survival in a Transgenic Mouse Model of ALS. Ann. Neurol. 2002;52:771&#x2013;778. doi: 10.1002/ana.10374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10374</ArticleId><ArticleId IdType="pubmed">12447931</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A.P., Chen C., Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 2001;49:176&#x2013;185. doi: 10.1002/1531-8249(20010201)49:2&lt;176::AID-ANA37&gt;3.0.CO;2-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;176::AID-ANA37&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">11220737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K., Tourtellotte W.W., McGeer E.G., McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord Implications for therapy. Neurology. 2001;57:952&#x2013;956. doi: 10.1212/WNL.57.6.952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.6.952</ArticleId><ArticleId IdType="pubmed">11571316</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.W., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L., Olszewski A., Stieg P., Lee J., Przedborski S., et al. Functional roles of caspase-1 and caspase-2 in an ALS transgenic mouse model. Science. 2000;288:335&#x2013;339. doi: 10.1126/science.288.5464.335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.288.5464.335</ArticleId><ArticleId IdType="pubmed">10764647</ArticleId></ArticleIdList></Reference><Reference><Citation>Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., Bonventre J.V., Woolf C.J. Interleukin-1 beta mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471&#x2013;475. doi: 10.1038/35068566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35068566</ArticleId><ArticleId IdType="pubmed">11260714</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogawa S., Zhang F.Y., Ross M.E., Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 1997;17:2746&#x2013;2755. doi: 10.1523/JNEUROSCI.17-08-02746.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-08-02746.1997</ArticleId><ArticleId IdType="pmc">PMC6573095</ArticleId><ArticleId IdType="pubmed">9092596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama M., Uchimura K., Zhu R.L., Nagayama T., Rose M.E., Stetler R.A., Isakson P.C., Chen J., Graham S.H. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. USA. 1998;95:10954&#x2013;10959. doi: 10.1073/pnas.95.18.10954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.18.10954</ArticleId><ArticleId IdType="pmc">PMC28002</ArticleId><ArticleId IdType="pubmed">9724811</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuno T., Nakatsuji Y., Kumanogoh A., Koguchi K., Moriya M., Fujimura H., Kikutani H., Sakoda S. Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: Relevance to amyotrophic lateral sclerosis. J. Neurochem. 2004;91:404&#x2013;412. doi: 10.1111/j.1471-4159.2004.02727.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02727.x</ArticleId><ArticleId IdType="pubmed">15447673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruusuvuori E., Kaila K. Carbonic anhydrases and Brain pH in the control of neuronal excitability. Subcell. Biochem. 2014;75:271&#x2013;290. doi: 10.1007/978-94-007-7359-2_14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-007-7359-2_14</ArticleId><ArticleId IdType="pubmed">24146384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumby S., Chung K.F., Adcock I.M. Transcriptional Effects of Ozone and Impact on Airway Inflammation. Front. Immunol. 2019;10:1610. doi: 10.3389/fimmu.2019.01610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01610</ArticleId><ArticleId IdType="pmc">PMC6635463</ArticleId><ArticleId IdType="pubmed">31354743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenci A., Macchia I., La Sorsa V., Sbarigia C., Di Donna V., Pietraforte D. Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. Front. Microbiol. 2022;13:871645. doi: 10.3389/fmicb.2022.871645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.871645</ArticleId><ArticleId IdType="pmc">PMC9069003</ArticleId><ArticleId IdType="pubmed">35531273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y.-H., Guan P.-P., Zhang S.-Q., Guo Y.-S., Wang P. Rofecoxib Attenuates the Pathogenesis of Amyotrophic Lateral Sclerosis by Alleviating Cyclooxygenase-2-Mediated Mechanisms. Front. Neurosci. 2020;14:817. doi: 10.3389/fnins.2020.00817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00817</ArticleId><ArticleId IdType="pmc">PMC7438558</ArticleId><ArticleId IdType="pubmed">32903591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M., Kipiani K., Petri S., Choi D.K., Chen J., Calingasan N.Y., Beal M.F. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2005;93:403&#x2013;411. doi: 10.1111/j.1471-4159.2005.03024.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03024.x</ArticleId><ArticleId IdType="pubmed">15816863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F.-C., Tsai C.-P., Kuang-Wu L.J., Wu M.-T., Tzu-Chi L.C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: A total population-based case-control study. JAMA Neurol. 2015;72:40&#x2013;48. doi: 10.1001/jamaneurol.2014.3367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3367</ArticleId><ArticleId IdType="pubmed">25383557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazato T., Kase R. Isolation of angiotensin-converting enzyme inhibitor from porcine plasma. Biochem. Biophys. Res. Commun. 1986;139:52&#x2013;55. doi: 10.1016/S0006-291X(86)80078-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(86)80078-X</ArticleId><ArticleId IdType="pubmed">3021131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Aluko R.E., Nakai S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: Quantitative structure&#x2212;activity relationship study of di- and tripeptides. J. Agric. Food Chem. 2006;54:732&#x2013;738. doi: 10.1021/jf051263l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf051263l</ArticleId><ArticleId IdType="pubmed">16448176</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Z.J., Jung W.K., Lee S.H., Byun H.G., Kim S.K. Antihypertensive effect of an angiotensin I-converting enzyme inhibitory peptide from bullfrog (Rana catesbeiana Shaw) muscle protein in spontaneously hypertensive rats. Process Biochem. 2007;42:1443&#x2013;1448. doi: 10.1016/j.procbio.2007.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.procbio.2007.05.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia K., Zhang L., Tang L., Huang T., Fan D. Assessing the role of blood pressure in amyotrophic lateral sclerosis: A Mendelian randomization study. Orphanet J. Rare Dis. 2022;17:56. doi: 10.1186/s13023-022-02212-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-022-02212-0</ArticleId><ArticleId IdType="pmc">PMC8848798</ArticleId><ArticleId IdType="pubmed">35172853</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Ichikawa Y., Igarash O., Ikeda K., Kinoshita M. Influence of temocapril on cultured ventral spinal cord neurons. Neurochem. Res. 2003;28:711&#x2013;714. doi: 10.1023/A:1022857632764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1022857632764</ArticleId><ArticleId IdType="pubmed">12716021</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdom C.J., Steyn F.J., Henderson R.D., McCombe P.A., Rogers M.-L., Ngo S.T. Biofluid Biomarkers of Amyotrophic Lateral Sclerosis. In: Philip V., Peplow B.M., Gennarelli T.A., editors. Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice. Springer; Berlin/Heidelberg, Germany:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1712-0_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Holst J.J. On the physiology of GIP and GLP-1. Horm. Metab. Res. 2004;36:747&#x2013;754. doi: 10.1055/s-2004-826158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2004-826158</ArticleId><ArticleId IdType="pubmed">15655703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Xue C., Zhu T., Vivekanandan A., Pennathur S., Ma Z.A., Chen Y.E. A tripeptide diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. PLoS ONE. 2013;8:e83509. doi: 10.1371/journal.pone.0083509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083509</ArticleId><ArticleId IdType="pmc">PMC3873933</ArticleId><ArticleId IdType="pubmed">24386218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004;89:2078&#x2013;2084. doi: 10.1210/jc.2003-031907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-031907</ArticleId><ArticleId IdType="pubmed">15126524</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen E.S., Deacon C.F., Holst J.J. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes. Metab. 2018;20:34&#x2013;41. doi: 10.1111/dom.13018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13018</ArticleId><ArticleId IdType="pubmed">28544214</ArticleId></ArticleIdList></Reference><Reference><Citation>Darsalia V., Orts&#xe4;ter H., Olverling A., Darl&#xf6;f E., Wolbert P., Nystr&#xf6;m T., Klein T., Sj&#xf6;holm &#xc5;., Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: A comparison with glimepiride. Diabetes. 2013;62:1289&#x2013;1296. doi: 10.2337/db12-0988.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0988</ArticleId><ArticleId IdType="pmc">PMC3609599</ArticleId><ArticleId IdType="pubmed">23209191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.L., Huang C.N. The neuroprotective effects of the anti-diabetic drug linagliptin against A&#x3b2;-induced neurotoxicity. Neural. Regen. Res. 2016;11:236&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810982</ArticleId><ArticleId IdType="pubmed">27073371</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveraux Q.L., Roy N., Stennicke H., Arsdale T., Zhou Q., Srinivasula S., Alnemri E., Salvesen S., Reed J. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215&#x2013;2223. doi: 10.1093/emboj/17.8.2215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/17.8.2215</ArticleId><ArticleId IdType="pmc">PMC1170566</ArticleId><ArticleId IdType="pubmed">9545235</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveraux Q.L., Leo E., Stennicke H., Welsh K., Salvesen G.S., Reed J. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242&#x2013;5251. doi: 10.1093/emboj/18.19.5242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.19.5242</ArticleId><ArticleId IdType="pmc">PMC1171595</ArticleId><ArticleId IdType="pubmed">10508158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootz H., Hansson I., Korhonen L., Lindholm D. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Exp. Cell Res. 2006;312:1890&#x2013;1898. doi: 10.1016/j.yexcr.2006.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2006.02.021</ArticleId><ArticleId IdType="pubmed">16566922</ArticleId></ArticleIdList></Reference><Reference><Citation>Guegan C., Vila M., Rosoklija G., Hays A.P., Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophiclateral sclerosis. J. Neurosci. 2001;21:6569&#x2013;6576. doi: 10.1523/JNEUROSCI.21-17-06569.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-17-06569.2001</ArticleId><ArticleId IdType="pmc">PMC6763092</ArticleId><ArticleId IdType="pubmed">11517246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Liang Y., Yamamoto M., Niwa J., Ando Y., Yoshihara T., Takeuchi H., Doyu M., Sobue G. X-Linked inhibitor of apoptosis protein is involved in mutant SOD1-mediated neuronal degeneration. J. Neurochem. 2002;82:576&#x2013;584. doi: 10.1046/j.1471-4159.2002.00998.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00998.x</ArticleId><ArticleId IdType="pubmed">12153481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufti A.R., Burstein E., Duckett C.S. XIAP: Cell death regulation meets copper homeostasis. Arch. Biochem. Biophys. 2007;463:168&#x2013;174. doi: 10.1016/j.abb.2007.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2007.01.033</ArticleId><ArticleId IdType="pmc">PMC1986780</ArticleId><ArticleId IdType="pubmed">17382285</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein E., Ganesh L., Dick R.D., van De Sluis B., Wilkinson J.C., Klomp L.W.J., Wijmenga C., Brewer G.J., Nabel G.J., Duckett C.S. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J. 2004;23:244&#x2013;254. doi: 10.1038/sj.emboj.7600031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600031</ArticleId><ArticleId IdType="pmc">PMC1271669</ArticleId><ArticleId IdType="pubmed">14685266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady G.F., Galban S., Liu X., Basrur V., Gitlin J.D., Elenitoba-Johnson K.S.J., Wilson T.E., Duckett C.S. Regulation of the Copper Chaperone CCS by XIAP-Mediated Ubiquitination. Mol. Cell. Biol. 2010;30:1923&#x2013;1936. doi: 10.1128/MCB.00900-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00900-09</ArticleId><ArticleId IdType="pmc">PMC2849478</ArticleId><ArticleId IdType="pubmed">20154138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Kanno T., Yanagisawa Y., Yasutake K., Hadano S., Yoshii F., Ikeda J.E. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011;232:41&#x2013;52. doi: 10.1016/j.expneurol.2011.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.08.001</ArticleId><ArticleId IdType="pubmed">21867702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Kanno T., Yanagisawa Y., Yasutake K., Inoue S., Hirayama N., Ikeda J.E. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS ONE. 2014;9:e87728. doi: 10.1371/journal.pone.0087728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087728</ArticleId><ArticleId IdType="pmc">PMC3909264</ArticleId><ArticleId IdType="pubmed">24498180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano O., Tanaka K., Kanno T., Iwasaki Y., Ikeda J.E. Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms. Sci. Rep. 2018;8:6. doi: 10.1038/s41598-017-18627-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18627-w</ArticleId><ArticleId IdType="pmc">PMC5758777</ArticleId><ArticleId IdType="pubmed">29311650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurjar R., Chan C., Curley P., Sharp J., Chiong J., Rannard S., Siccardi M., Owen A. Inhibitory effects of commonly used excipients on P-glycoprotein in vitro. Mol. Pharm. 2018;15:4835&#x2013;4842. doi: 10.1021/acs.molpharmaceut.8b00482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00482</ArticleId><ArticleId IdType="pubmed">30350641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatoki T.H., Awofisayo O.A., Ibraheem O., Oyedele A.S., Akinlolu O.S. In silico Investigation of First-Pass Effect on Selected Small Molecule Excipients and Structural Dynamics of P-glycoprotein. Bioinform. Biol. Insight. 2020;14:1&#x2013;9. doi: 10.1177/1177932220943183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1177932220943183</ArticleId><ArticleId IdType="pmc">PMC7385845</ArticleId><ArticleId IdType="pubmed">32782427</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Sanberg P.R. Blood-CNS barrier impairment in ALS patients versus an animal model. Front. Cell Neurosci. 2014;8:21. doi: 10.3389/fncel.2014.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00021</ArticleId><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed L.A., Markandaiah S., Bonanno S., Pasinelli P., Trotti D. Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. AAPS J. 2017;19:1600&#x2013;1614. doi: 10.1208/s12248-017-0120-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-017-0120-6</ArticleId><ArticleId IdType="pmc">PMC6571115</ArticleId><ArticleId IdType="pubmed">28779378</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H., Lichter J., Sarlo M., Markandaiah S.S., McAvoy K., Richard J.P., Jablonski M.R., Maragakis N.J., Pasinelli P., Trotti D. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia. 2016;64:1298&#x2013;1313. doi: 10.1002/glia.23003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23003</ArticleId><ArticleId IdType="pmc">PMC5541958</ArticleId><ArticleId IdType="pubmed">27158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch R., Renard B.Y. Docking small peptides remains a great challenge: An assessment using AutoDock Vina. Brief. Bioinform. 2015;16:1045&#x2013;1056. doi: 10.1093/bib/bbv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbv008</ArticleId><ArticleId IdType="pubmed">25900849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong F., Krishnan A., Zheng E.J., Stark H., Manson A.L., Earl A.M., Jaakkola T., Collins J.J. Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery. Mol. Syst. Biol. 2022;18:e11081. doi: 10.15252/msb.202211081.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.202211081</ArticleId><ArticleId IdType="pmc">PMC9446081</ArticleId><ArticleId IdType="pubmed">36065847</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., van der Spek R.A.A., Bakker M.K., van Vugt J.J.F.A., Hop P.J., Zwamborn R.A., De Klein N., Westra H.J., Bakker O.B., Deelen P., et al. Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. medRxiv. 2021 doi: 10.1101/2021.03.12.21253159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.12.21253159</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke D.J.B., Kuleshov M.V., Schilder B.M., Torre D., Duffy M.E., Keenan A.B., Lachmann A., Feldmann A.S., Gundersen G.W., Silverstein M.C., et al. eXpression2Kinases (X2K) Web: Linking expression signatures to upstream cell signaling networks. Nucleic Acids Res. 2018;46:171&#x2013;179. doi: 10.1093/nar/gky458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky458</ArticleId><ArticleId IdType="pmc">PMC6030863</ArticleId><ArticleId IdType="pubmed">29800326</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A.L., Nastou K.C., Lyon D., Kirsch R., Pyysalo S., Doncheva N.T., Legeay M., Fang T., Bork P., et al. The STRING database in 2021: Customizable protein&#x2013;protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605&#x2013;D612. doi: 10.1093/nar/gkaa1074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1074</ArticleId><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi C., Fassi E.M.A., Li J., Bartolomei M., Benigno G., Roda G., Arnoldi A., Grazioso G. Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity. Pharmaceutics. 2022;14:665. doi: 10.3390/pharmaceutics14030665.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14030665</ArticleId><ArticleId IdType="pmc">PMC8951016</ArticleId><ArticleId IdType="pubmed">35336039</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacila G., Sari Y. Potential Therapeutic Drugs and Methods for the Treatment of Amyotrophic Lateral Sclerosis. Curr. Med. Chem. 2014;21:3583&#x2013;3593. doi: 10.2174/0929867321666140601162710.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140601162710</ArticleId><ArticleId IdType="pmc">PMC4182116</ArticleId><ArticleId IdType="pubmed">24934355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori Y., Asakura S., Yamamoto A., Odagiri S., Yamada D., Sekiguchi M., Wada K., Sato M., Kurabayashi A., Suzuki H., et al. Characterization of soy-deprestatin, a novel orally active decapeptide that exerts antidepressant-like effects via gut-brain communication. FASEB J. 2018;32:568&#x2013;575. doi: 10.1096/fj.201700333RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700333RR</ArticleId><ArticleId IdType="pubmed">28970253</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkiewicz P., Iwaniak A., Darewicz M. BIOPEP-UWM Database of Bioactive Peptides: Current Opportunities. Int. J. Mol. Sci. 2019;20:5978. doi: 10.3390/ijms20235978.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20235978</ArticleId><ArticleId IdType="pmc">PMC6928608</ArticleId><ArticleId IdType="pubmed">31783634</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A., Michielin O., Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357&#x2013;W364. doi: 10.1093/nar/gkz382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz382</ArticleId><ArticleId IdType="pmc">PMC6602486</ArticleId><ArticleId IdType="pubmed">31106366</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A., Michielin O., Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of small molecules. Scientific Rep. 2017;7:42717. doi: 10.1038/srep42717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42717</ArticleId><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov I., Bangov I., Flower D.R., Doytchinova I. AllerTOP v.2-a server for in silico prediction of allergens. J. Mol. Model. 2014;20:2278. doi: 10.1007/s00894-014-2278-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00894-014-2278-5</ArticleId><ArticleId IdType="pubmed">24878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetenyi C., van der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 2002;11:1729&#x2013;1737. doi: 10.1110/ps.0202302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.0202302</ArticleId><ArticleId IdType="pmc">PMC2373668</ArticleId><ArticleId IdType="pubmed">12070326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciemny M., Kurcinski M., Kamel K., Kolinski A., Alam N., Schueler-Furman O., Kmiecik S. Protein&#x2013;peptide docking: Opportunities and challenges. Drug Discovery Today. 2018;23:1530&#x2013;1537. doi: 10.1016/j.drudis.2018.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2018.05.006</ArticleId><ArticleId IdType="pubmed">29733895</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Jin B., Li H., Huang S.-Y. HPEPDOCK: A web server for blind peptide-protein docking based on a hierarchical algorithm. Nucleic. Acids Res. 2018;6:W443&#x2013;W450. doi: 10.1093/nar/gky357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky357</ArticleId><ArticleId IdType="pmc">PMC6030929</ArticleId><ArticleId IdType="pubmed">29746661</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455&#x2013;461. doi: 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt J., Santos-Martins D., Tillack A.F., Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 2021;61:8. doi: 10.1021/acs.jcim.1c00203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c00203</ArticleId><ArticleId IdType="pubmed">34278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785&#x2013;2791. doi: 10.1002/jcc.21256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21256</ArticleId><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Stierand K., Maa&#xdf; P.C., Rarey M. Molecular complexes at a glance: Automated generation of two-dimensional complex diagrams. Bioinformatics. 2006;22:1710&#x2013;1716. doi: 10.1093/bioinformatics/btl150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btl150</ArticleId><ArticleId IdType="pubmed">16632493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>